Treatment of non promyelocytic acute myeloid leukemia in elderly patients by low dose cytozar plus Arsenic trioxide

Feasibility study of treatment of non promyelocytic acute myeloid leukemia in elderly patients by low dose cytozar plus Arsenic trioxide on ambulatory schedule

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138711061030N5

Enrollment

Registered

2009-02-16

Start date

2007-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukaemia. Acute myeloid leukaemia

Interventions

Intervention 1: Cytozar 20 mg /q12h/ sc/10d/q28d for 2 cycle. Intervention 2: Arsenic 10mg/infusion2h/iv/DW5% d1-d5,d7-d11.

Cytozar 20 mg /q12h/ sc/10d/q28d for 2 cycle

Arsenic 10mg/infusion2h/iv/DW5% d1-d5,d7-d11

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Elderly patients with non promyelocytic AML, Performance status (ECOG) 3 or 4 Exclusion criteria: Age 2

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Response Rate. Timepoint: 1, 2, 6 month and one year after intervention. Method of measurement: Bone Marrow Aspiration and Biopsy and complete blood count.	—

Secondary

Measure	Time frame
Overal Survival. Timepoint: One year after intervention. Method of measurement: Survey of patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seyed Mehdi Hashemi

Hematology-Oncology and SCT Research Center

horcbmt@sina.tums.ac.ir+98 21 8490 2635

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026